In the past week, MBRX stock has gone down by -17.46%, with a monthly decline of -45.83% and a quarterly plunge of -55.17%. The volatility ratio for the week is 9.86%, and the volatility levels for the last 30 days are 16.96% for Moleculin Biotech Inc The simple moving average for the past 20 days is -11.94% for MBRX’s stock, with a -57.87% simple moving average for the past 200 days.
Is It Worth Investing in Moleculin Biotech Inc (NASDAQ: MBRX) Right Now?
Additionally, the 36-month beta value for MBRX is 2.15. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 2 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for MBRX is 13.19M and currently, short sellers hold a 8.20% ratio of that float. The average trading volume of MBRX on March 20, 2025 was 5.79M shares.
MBRX) stock’s latest price update
The stock price of Moleculin Biotech Inc (NASDAQ: MBRX) has dropped by -4.59 compared to previous close of 1.09. Despite this, the company has seen a fall of -17.46% in its stock price over the last five trading days. globenewswire.com reported 2025-03-19 that HOUSTON, March 19, 2025 (GLOBE NEWSWIRE) — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced that it will report its financial results for the year ended December 31, 2024, on Friday afternoon, March 21, 2025. Moleculin management will host a conference call and live audio webcast to discuss the operational and financial results on Monday morning, March 24, 2025 at 8:30 AM ET.
Analysts’ Opinion of MBRX
Oppenheimer, on the other hand, stated in their research note that they expect to see MBRX reach a price target of $14. The rating they have provided for MBRX stocks is “Outperform” according to the report published on July 18th, 2022.
MBRX Trading at -24.14% from the 50-Day Moving Average
After a stumble in the market that brought MBRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -88.25% of loss for the given period.
Volatility was left at 16.96%, however, over the last 30 days, the volatility rate increased by 9.86%, as shares sank -41.24% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -41.90% lower at present.
During the last 5 trading sessions, MBRX fell by -17.46%, which changed the moving average for the period of 200-days by -77.59% in comparison to the 20-day moving average, which settled at $1.1810. In addition, Moleculin Biotech Inc saw -38.82% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for MBRX
Current profitability levels for the company are sitting at:
- -71.22 for the present operating margin
- 0.76 for the gross margin
The net margin for Moleculin Biotech Inc stands at -74.26. The total capital return value is set at -1.62. Equity return is now at value -141.49, with -95.84 for asset returns.
Based on Moleculin Biotech Inc (MBRX), the company’s capital structure generated 0.06 points at debt to capital in total, while cash flow to debt ratio is standing at -47.8. The debt to equity ratio resting at 0.07. The interest coverage ratio of the stock is -65.87.
Currently, EBITDA for the company is -29.5 million with net debt to EBITDA at 0.31. When we switch over and look at the enterprise to sales, we see a ratio of 12.16. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.08.
Conclusion
In conclusion, Moleculin Biotech Inc (MBRX) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
